6 most recent filings and news items mentioning ABCL. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/ABCL/news?limit=20"
Pull ABCL filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayAbCellera Biologics will release Phase 2 trial data for ABCL635 on Monday, August 10, 2026. This potential first-in-class antibody for menopause symptoms is expected to drive investor attention and market speculation regarding the company's pipeline valuations.
View filing at SEC.gov →AbCellera announced $4.1M in total revenue and expanded its T-cell engager platform with new multi-billion dollar collaborations to Jazz and Vertex. With over $675M in liquidity, the company also expects top-line data from its ABCL635 study to be read out shortly.
View filing at SEC.gov →AbCellera collaborated with Vertex Pharmaceuticals to develop multispecific T-cell engagers, receiving $28.1 million in upfront payments. The deal strengthens AbCellera's position in the advanced autoimmune and immunology markets.
View filing at SEC.gov →AbCellera Biologics appointed Dr. Lynn Seely as an independent director. Seely's biopharmaceutical experience may bolster the company's strategic leadership.
View filing at SEC.gov →Jazz Pharmaceuticals and AbCellera announced a collaboration to discover next-generation T-cell engaging multispecific antibodies, with Jazz paying $56 million upfront and eligible for up to $792 million in milestone payments per program. The partnership expands Jazz's oncology
View filing at SEC.gov →AbCellera appointed Dr. Victor Sandor, an experienced medical oncologist and former CMO at Array BioPharma, to its Board of Directors. The appointment strengthens the company's leadership as it advances its antibody discovery pipeline toward clinical outcomes.
View filing at SEC.gov →